OptiBiotix Health - License and supply agreement with Genuine Health
OptiBiotix Health plc
("OptiBiotix" or the "Company")
License and supply agreement with Genuine Health
LPLDL® license for
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that its wholly-owned subsidiary, ProBiotix Health Ltd. ("ProBiotix"), has granted a non-exclusive LPLDL® license to Genuine Health Inc. ("Genuine Health") for a cardiovascular health product in
Genuine Health (https://www.genuinehealth.com/en-ca/) is an established Canadian natural health company that has been formulating natural products for more than 25 years. The company makes greens+, omegas, proteins and probiotics. Genuine Health's greens+ is the #1 superfood in
As part of the agreement, Genuine Health will submit products containing LPLDL® for cardiovascular and other health claims to Health Canada, a department of the Government of Canada responsible for the country's federal health policy. The Company believes that if registration is successful LPLDL® will be the first probiotic supplement in the Canadian market to obtain a specific health claim for cardiovascular health.
This agreement is another step in building brand and product presence in the large North American market as a dietary supplement, a live biotherapeutic product (LBP), or a functional ingredient. The agreement is for an initial period of 36 months.
presented in different presentations and formulations, for cardiovascular health in both consumer and pharmaceutical markets around the world."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
The Directors of the Company accept responsibility for the content of this announcement
For further information, please contact:
OptiBiotix Health plc
| || |
Contact via Walbrook below
Cairn Financial Advisers LLP (NOMAD)
Tel: 020 7213 0880
Tel: 020 7220 0500
Walbrook PR Ltd
Mob: 07876 741 001
| || |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identiﬁed by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding OptiBiotix's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reﬂect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.
Quick facts: OptiBiotix Health PLC
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE